Polatuzumab Vedotin–Based Regimen Improves Overall Survival in Refractory DLBCL

1. POLARGO trial combined polatuzumab vedotin with R-GemOx. 2. Improved overall survival from 12.5 to 19.5 months. 3. 40% reduction in deaths observed. 4. Increased toxicity noted with treatment. 5. Enhanced response rate: 52.7% vs 24.6%. 6. Focus on transplant-ineligible DLBCL patients. 7. Safety profile included thrombocytopenia and infections. 8. Results maintained across stratified patient groups.